Frailty and circulating markers of inflammation in HIV+ and HIV2 men in the multicenter AIDS cohort study

Journal of Acquired Immune Deficiency Syndromes

Volumn 74, Issue 4, 2017, Pages 407-417

  Margolick, Joseph B ^a   Bream, Jay H ^a   Martínez Maza, Otoniel ^b   Lopez, Joe ^a   Li, Xiuhong ^a   Phair, John P ^c   Koletar, Susan L ^d   Jacobson, Lisa P ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d OHIO UNIVERSITY   (United States)

Author keywords

C reactive protein; chemokines; cohort study; cytokines; frailty; HIV

Indexed keywords

B CELL ACTIVATING FACTOR; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD14 ANTIGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AGE; ARTICLE; B LYMPHOCYTE ACTIVATION; BODY MASS; COHORT ANALYSIS; COMORBIDITY; EDUCATIONAL STATUS; FRAILTY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; MIDDLE AGED; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RACE; SMOKING; T LYMPHOCYTE; AGING; CLINICAL TRIAL; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; LONGITUDINAL STUDY; LYMPHOCYTE ACTIVATION; METABOLISM; MULTICENTER STUDY; PHYSIOLOGY; PROCEDURES; SERODIAGNOSIS; UNITED STATES;

AGING; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOMARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HIV-1; HUMANS; INFLAMMATION; LONGITUDINAL STUDIES; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; UNITED STATES;

EID: 85015854304     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000001261     Document Type: Article

References (47)

1. Wada N, Jacobson LP, Cohen M, et al. Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008. Am J Epidemiol. 2013;177:116-125.
2. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2011;62:141-155.
3. Regidor DL, Detels R, Breen EC, et al. Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation. AIDS. 2011;25:303-314.
4. Bandeen-Roche K, Xue QL, Ferrucci L, et al. Phenotype of frailty: Characterization in the women's health and aging studies. J Gerontol A Biol Sci Med Sci. 2006;61:262-266.
5. Fried L, Tangen CM, Walston J, et al. Frailty in older adults: Evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56A:M146-M156.
6. Althoff KN, Jacobson LP, Cranston RD, et al. Age, comorbidities and AIDS predict the frailty phenotype in men who have sex with men. J Gerontol A Biol Sci Med Sci. 2014;69A:189-198.
7. Fried LP, Xue QL, Cappola AR, et al. Nonlinear multisystem physiological dysregulation associated with frailty in older women: Implications for etiology and treatment. J Gerontol A Biol Sci Med Sci. 2009;64:1049-1057.
8. Morley JE, Vellas B, van Kan GA, et al. Frailty consensus: A call to action. J Am Med Dir Assoc. 2013;14:392-397.
9. Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. Lancet. 2013; 381:752-762.
10. Yao X, Li H, Leng SX. Inflammation and immune system alterations in frailty. Clin Geriatr Med. 2011;27:79-87.
11. Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999;106:506-512.
12. Ferrucci L, Penninx BW, Volpato S, et al. Change in muscle strength explains accelerated decline of physical function in older women with high interleukin-6 serum levels. J Am Geriatr Soc. 2002;50: 1947-1954.
13. Collerton J, Martin-Ruiz C, Davies K, et al. Frailty and the role of inflammation, immunosenescence and cellular ageing in the very old: Cross-sectional findings from the Newcastle 85+ Study. Mech Ageing Dev. 2012;133:456-466.
14. De Martinis M, Franceschi C, Monti D, et al. Inflammation markers predicting frailty and mortality in the elderly. Exp Mol Pathol. 2006;80: 219-227.
15. Leng SX, Tian X, Matteini A, et al. IL-6-independent association of elevated serum neopterin levels with prevalent frailty in communitydwelling older adults. Age Ageing. 2011;40:475-481.
16. Desquilbet L, Jacobson L, Fried LP, et al. HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol A Biol Sci Med Sci. 2007;62:1279-1286.
17. Rees HC, Ianas V, McCracken P, et al. Measuring frailty in HIV-infected individuals. Identification of frail patients is the first step to amelioration and reversal of frailty. J Vis Exp. 2013;77:e50537.
18. Kooij KW, Wit FW, Schouten J, et al. HIV infection is independently associated with frailty in middle-aged HIV type 1-infected individuals compared with similar but uninfected controls. AIDS. 2016;30: 241-250.
19. Greene M, Covinsky KE, Valcour V, et al. Geriatric syndromes in older HIV-infected adults. J Acquir Immune Defic Syndr. 2015;69:161-167.
20. Brothers TD, Kirkland S, Guaraldi G, et al. Frailty in people aging with human immunodeficiency virus (HIV) infection. J Infect Dis. 2014;210: 1170-1179.
21. Piggott DA, Muzaale AD, Mehta SH, et al. Frailty, HIV infection, and mortality in an aging cohort of injection drug users. PLoS One. 2013;8: E54910.
22. Akgun KM, Tate JP, Crothers K, et al. An adapted frailty-related phenotype and the VACS index as predictors of hospitalization and mortality in HIV-infected and uninfected individuals. J Acquir Immune Defic Syndr. 2014;67:397-404.
23. Piggott DA, Varadhan R, Mehta SH, et al. Frailty, inflammation, and mortality among persons aging with HIV infection and injection drug use. J Gerontol A Biol Sci Med Sci. 2015;70:1542-1547.
24. Kaslow RA, Ostrow DG, Detels R, et al. The Multicenter AIDS Cohort Study: Rationale, organization, and selected characteristics of the participants. Am J Epidemiol. 1987;126:310-318.
25. Brown T, Wang Z, Chu H, et al. Longitudinal anthropometric changes in HIV-infected and HIV-uninfected men. J Acquir Immune Defic Syndr. 2006;43:356-362.
26. Wada NI, Jacobson LP, Margolick JB, et al. The effect of HAARTinduced HIV suppression on circulating markers of inflammation and immune activation. AIDS. 2015;29:463-471.
27. McKay HS, Margolick JB, Martinez-Maza O, et al. Multiplex assay reliability and long-term intra-individual variation of serologic inflammatory biomarkers. Cytokine. 2017;90:185-192.
28. Chowdhury F, Williams A, Johnson P. Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling. J Immunol Methods. 2009;340:55-64.
29. CDC. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41:1-19.
30. Cox C, Chu H, Schneider MF, et al. Parametric survival analysis and taxonomy of hazard functions for the generalized gamma distribution. Stat Med. 2007;26:4352-4357.
31. Ershler WB. Interleukin-6: A cytokine for gerontologists. J Am Geriatr Soc. 1993;41:176-181.
32. Erlandson KM, Allshouse AA, Jankowski CM, et al. Association of functional impairment with inflammation and immune activation in HIV type 1-infected adults receiving effective antiretroviral therapy. J Infect Dis. 2013;208:249-259.
33. Shah S, Ma Y, Scherzer R, et al. Association of HIV, hepatitis C virus and liver fibrosis severity with interleukin-6 and C-reactive protein levels. AIDS. 2015;29:1325-1333.
34. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc. 1995;57:289-300.
35. Desquilbet L, Jacobson L, Fried LP, et al. A frailty-related phenotype before HAART initiation as an independent risk factor for AIDS or death after HAART among HIV-infected men. J Gerontol A Biol Sci Med Sci. 2011;66A:1030-1038.
36. Haeseker MB, Pijpers E, Dukers-Muijrers NH, et al. Association of cytomegalovirus and other pathogens with frailty and diabetes mellitus, but not with cardiovascular disease and mortality in psycho-geriatric patients; a prospective cohort study. Immun Ageing. 2013;10:30.
37. Matheï C, Vaes B, Wallemacq P, et al. Associations between cytomegalovirus infection and functional impairment and frailty in the BELFRAIL Cohort. J Am Geriatr Soc. 2011;59:2201-2208.
38. Schmaltz HN, Fried LP, Xue QL, et al. Chronic cytomegalovirus infection and inflammation are associated with prevalent frailty in community-dwelling older women. J Am Geriatr Soc. 2005;53:747-754.
39. Vallejo AN, Hamel DL Jr, Mueller RG, et al. NK-like T cells and plasma cytokines, but not anti-viral serology, define immune fingerprints of resilience and mild disability in exceptional aging. PLoS One. 2011;6: E26558.
40. Wang GC, Kao WH, Murakami P, et al. Cytomegalovirus infection and the risk of mortality and frailty in older women: A prospective observational cohort study. Am J Epidemiol. 2010;171:1144-1152.
41. Michaud M, Balardy L, Moulis G, et al. Proinflammatory cytokines, aging, and age-related diseases. J Am Med Dir Assoc. 2013;14:877-882.
42. Ferrando-Martinez S, Ruiz-Mateos E, Casazza JP, et al. IFNgamma-TNFalpha-IL2-MIP1alpha-CD107a+PRF1+ CD8 pp65-specific T-cell response is independently associated with time to death in elderly humans. J Gerontol A Biol Sci Med Sci. 2014;70:1210-1218.
43. Compte N, Zouaoui BK, Vanhaeverbeek M, et al. Frailty in old age is associated with decreased interleukin-12/23 production in response to toll-like receptor ligation. PLoS One. 2013;8:e65325.
44. Tchkonia T, Zhu Y, van DJ, et al. Cellular senescence and the senescent secretory phenotype: Therapeutic opportunities. J Clin Invest. 2013;123: 966-972.
45. Jylhävä J, Nevalainen T, Marttila S, et al. Characterization of the role of distinct plasma cell-free DNA species in age-associated inflammation and frailty. Aging Cell. 2013;12:388-397.
46. Ryan SO, Johnson JL, Cobb BA. Neutrophils confer T cell resistance to myeloid-derived suppressor cell-mediated suppression to promote chronic inflammation. J Immunol. 2013;190:5037-5047.
47. Zhang W, Nilles TL, Johnson JR, et al. Regulatory T cells, frailty, and immune activation in men who have sex with men in the Multicenter AIDS Cohort Study. J Gerontol A Biol Sci Med Sci. 2015;70:1533-1541.